75000 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS
link:presentationLink
link:calculationLink
link:definitionLink
75090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75100 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance
link:presentationLink
link:calculationLink
link:definitionLink
995457 - Disclosure - Organization and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995467 - Disclosure - Cash and Investments in Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995477 - Disclosure - Consolidated Financial Statement Details
link:presentationLink
link:calculationLink
link:definitionLink
995487 - Disclosure - Equity Method Investment
link:presentationLink
link:calculationLink
link:definitionLink
995497 - Disclosure - Operating Leases
link:presentationLink
link:calculationLink
link:definitionLink
995507 - Disclosure - Liabilities Related to the Sales of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995517 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995527 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995537 - Disclosure - License and Collaboration Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995547 - Disclosure - Restructuring and Impairment
link:presentationLink
link:calculationLink
link:definitionLink
995557 - Disclosure - Gain on Sale of the Huntsville Manufacturing Facility
link:presentationLink
link:calculationLink
link:definitionLink
995567 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995577 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995587 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995597 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995607 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995617 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995627 - Disclosure - Cash and Investments in Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995637 - Disclosure - Consolidated Financial Statement Details (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995647 - Disclosure - Equity Method Investment (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995657 - Disclosure - Operating Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995667 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995677 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995687 - Disclosure - Restructuring and Impairment (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995697 - Disclosure - Gain on Sale of the Huntsville Manufacturing Facility (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995707 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995717 - Disclosure - Income Taxes (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995727 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995737 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995747 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995757 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995767 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995777 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995787 - Disclosure - Consolidated Financial Statement Details - Schedule of Other Current Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995797 - Disclosure - Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995807 - Disclosure - Equity Method Investment - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995817 - Disclosure - Equity Method Investment - Schedule of equity method investment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995827 - Disclosure - Property, Plant and Equipment - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995837 - Disclosure - Operating Leases - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995847 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995857 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995867 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995877 - Disclosure - Operating Leases - Schedule of Maturities of Operating Lease Receivables from Subleases (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995887 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995897 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995907 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995917 - Disclosure - Stockholders Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995927 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995937 - Disclosure - License and Collaboration Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995947 - Disclosure - Restructuring and Impairment - Additional information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995957 - Disclosure - Restructuring and Impairment - Summary of Restructuring Plans, Restructuring and Impairment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995967 - Disclosure - Restructuring and Impairment - Sublease Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995977 - Disclosure - Restructuring and Impairment - Restructuring Reserve Rollforward (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995987 - Disclosure - Gain on Sale of the Huntsville Manufacturing Facility - Schedule of Assumptions Used to Calculate the Fair Value of the Equity Method Investment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995997 - Disclosure - Gain on Sale of the Huntsville Manufacturing Facility - Summary of Gain Computation (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996007 - Disclosure - Stock-Based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996017 - Disclosure - Stock-Based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996027 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996037 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996047 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996057 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996067 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996077 - Disclosure - Income Taxes - Schedule of Benefit for Income Taxes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996087 - Disclosure - Income Taxes - Schedule of Reconciliation of our U.S. Federal Statutory Tax Amount and Rate to Effective Amount and Rate (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996097 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996107 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996117 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996127 - Disclosure - Segment Reporting - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996137 - Disclosure - Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996147 - Disclosure - Segment Reporting - Schedule of Other Segment Expense Items Included within Net Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996157 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996167 - Disclosure - Subsequent Events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Vested and released (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Segments [Domain]
Foreign
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Restructuring Reserve
Restructuring Reserve, Total
Restructuring reserve, beginning balance
Restructuring reserve, ending balance
Concentration Risk Type
Concentration Risk Type [Axis]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred stock, shares issued (in shares)
Preferred Stock, Shares Issued
Statement of Financial Position Location, Balance [Domain]
Balance Sheet Location [Domain]
Reverse Stock Split
Reverse Stock Split [Policy Text Block]
Disclosure of reverse stock split policy
Disposal Group, Including Discontinued Operation, Inventory, Current
Inventory
Accounts payable
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accounts Payable, Total
Non-cash investing and financing activities:
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Plan Name
Plan Name [Axis]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Investments in continuous unrealized loss positions for 12 months or longer
Equity [Abstract]
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Share issued base value
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options Shares Issued Price Per Unit
Share based compensation arrangement by share based payment award, equity instruments other than options shares issued price per unit.
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
Accounts receivable
Level 2
Fair Value, Inputs, Level 2 [Member]
Total deferred tax assets
Deferred Tax Assets, Net of Valuation Allowance
Weighted- Average Exercise Price per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, shares authorized (in shares)
Common Stock, Shares Authorized
Common stock, number of authorized
Net accounts receivable
Accounts Receivable, after Allowance for Credit Loss
Accounts Receivable, after Allowance for Credit Loss, Total
Net capital loss carryforwards
Deferred Tax Assets, Capital Loss Carryforwards
Effective Date of Warrant
Effective date of warrant.
Effective date of warrant
Product and Service
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
ASU 2023-09
Accounting Standards Update 2023-09 [Member]
Entity Shell Company
Entity Shell Company
Other accrued expenses
Other Accrued Liabilities, Current
Cash and cash equivalents
Cash and cash equivalents
Cash and Cash Equivalent
Cash and Cash Equivalents, at Carrying Value, Total
Percentage Of Ownership Received in Asset Acquisition
Percentage of ownership received in asset acquisition.
Ownership interest received
Milestone [Domain]
Milestone [Domain]
Milestone
Operating Lease, Impairment Loss
Total impairment of lease assets
Book value in excess of fair value
Total impairment of lease assets
Impairment charges
Asset Acquisition By Ampersand Capital Partners [Member]
Asset acquisition by ampersand capital partners.
Asset Acquisition By Ampersand Capital Partners
Subsidiary, Sale of Stock [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Lease space (in sq ft)
Area Of Leased Space
Area of leased space.
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Huntsville Manufacturing Facility
Huntsville Manufacturing Facility
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Common stock, shares issued (in shares)
Common Stock, Shares, Issued
Common shares issued
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Asset Class [Domain]
Asset Class [Domain]
Statement [Table]
Statement [Table]
Share-based compensation plan's share limit reduction for every one restricted stock unit granted
Share Based Compensation Plans Share Limit For Every One Share
Share based compensation plan's share limit for every one share.
Additions
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Operating Loss Carryforwards, Expiration Date
Operating loss carryforwards, expiration beginning date
Weighted-average grant-date fair value of options granted (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Purchase price of common stock, percent
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Statement [Line Items]
Statement [Line Items]
Treasury Stock, Value, Acquired, Cost Method
Repurchase of common stock from Bristol-Myers Squibb
Repurchase of common stock from Bristol-Myers Squibb
Revenue Recognition
Revenue from Contract with Customer [Policy Text Block]
Pre Funded Warrant [Member]
Pre Funded Warrant.
Pre-Funded Warrant
Facilities costs
Facilities Costs
Facilities costs.
Entity Filer Category
Entity Filer Category
Two Thousand Twenty Six Public Offering [Member]
Two thousand twenty six public offering.
2026 Offering
Units Issued
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Total liabilities and stockholders’ equity
Liabilities and Equity
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total
Changes in unrecognized tax benefits
Asset Acquisition by Nova
Asset Acquisition by Nova [Member]
Asset Acquisition by Nova [Member]
Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Restructuring Type [Axis]
Restructuring Type [Axis]
Property, Plant and Equipment, Type
Long-Lived Tangible Asset [Axis]
Measurement Input, Interest Rate
Measurement Input, Inception Discount Rate [Member]
Increase in valuation allowance
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Prepaid Expenses and Other Current Assets [Member]
Other prepaid expenses
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Eli Lilly
Eli Lilly [Member]
Eli Lilly.
Restructuring and Related Costs [Table Text Block]
Schedule of Restructuring and Impairment
Deferred Revenue [Domain]
Valuation allowance for deferred tax assets
Deferred Tax Assets, Valuation Allowance
Reimbursement of expenses
Reimbursement Of Expenses
Reimbursement of expenses.
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
U.S. Federal Statutory Tax Rate
Shares Issued, Price Per Share
Shares issued, price per share
Subsequent Event [Line Items]
Cybersecurity Risk Management Third Party Engaged [Flag]
Documents Incorporated by Reference
Documents Incorporated by Reference [Text Block]
Two Thousand And Twenty Five Inducement Plan [Member]
Two Thousand And Twenty Five Inducement Plan [Member].
2025 Inducement Plan
Received upfront and milestone payment
Upfront And Milestone Payments Received Under License Agreement
Upfront and milestone payments received under license agreement.
Effective Income Tax Rate Reconciliation, Percent
Effective Tax Rate
Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits
Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits
Changes in unrecognized tax benefits
Investment Income, Interest
Interest income
Income Tax Authority
Income Tax Jurisdiction [Axis]
Long-term investments
Long-term investments
Debt Securities, Available-for-Sale, Noncurrent
Geographical
Geographical [Domain]
Percentage of gross sale of common stock sold through sales agents commission rate
Percentage of Gross Sale of Common Stock Sold through Sales Agents Commission Rate
Percentage of gross sale of common stock sold through sales agents commission rate.
Sale of stock upon exercise of option to purchase additional shares of common stock
Sale Of Stock Upon Exercise Of Option To Purchase Additional Shares Of Common Stock
Sale of stock upon exercise of option to purchase additional shares of common stock.
Percentage of sharing development costs
Percentage Of Sharing In Development Costs
Percentage of sharing in development costs.
Capital in excess of par value
Additional Paid in Capital, Common Stock
Liability Related To The Sale Of Future Royalties [Roll Forward]
Liability Related To The Sale Of Future Royalties [Roll Forward]
Liability Related To The Sale Of Future Royalties [Roll Forward]
Rezpegaldesleukin [Member]
Rezpegaldesleukin.
Rezpegaldesleukin (IL-2 receptor agonist/regulatory T cell agent)
Related Party [Member]
Related Party
Equity Method Investment Dividends or Distributions per Unit
Equity method investment dividends or distributions per unit.
Equity method investment dividends or distributions per unit
Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate
BMS
Bristol Myers Squibb Company [Member]
Bristol-Myers Squibb Company.
Bristol Myers Squibb Company
Options granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Restructuring Costs and Asset Impairment Charges
Restructuring and impairment
Restructuring and impairment
Contract Termination and Other Costs Included in Accrued Expenses
Contract termination and other costs included in accrued expenses.
Contract termination and other costs included in accrued expenses
Investment, Name [Axis]
Basic net loss per share (in dollars per share)
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Basic net loss per share (in dollars per share)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Foreign currency translation gain
Net foreign currency translation adjustment
Outstanding, beginning balance (in shares)
Outstanding, ending balance (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Stock options outstanding
Total common stock reserved for issuance
Total current liabilities
Liabilities, Current
Unrecognized tax benefits, penalties recognized
Unrecognized Tax Benefits, Income Tax Penalties Expense
Accounts receivable
Increase (Decrease) in Accounts Receivable
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Revenue, Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Liability Related To Sale Of Future Royalties [Table]
Liability Related To Sale Of Future Royalties [Table]
Liability related to sale of future royalties.
Federal
Domestic Tax Jurisdiction [Member]
Nektar's
Parent Company [Member]
Additions
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Accounting Standards Update [Axis]
Consolidation Items
Consolidation Items [Domain]
Preferred Unit, Price Per Unit Owned by Related Party
Preferred unit, price per unit owned by related party.
Preferred unit, price per unit owned by related party
Stockholders’ equity:
Equity, Attributable to Parent [Abstract]
Entity Small Business
Entity Small Business
Gain on Sale of The Huntsville Manufacturing Facility
Gain on sale of the huntsville manufacturing facility
Gain on sale of the Huntsville manufacturing facility
Gain on sale of the Huntsville manufacturing facility
Payable For Newdrug Investigle Milestone
Payable for newdrug investigle milestone.
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Total
Stock-based compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Tax positions related to prior years:
Tax Positions Related To Prior Years [Abstract]
Tax Positions Related To Prior Years
Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount
Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total
Effects of cross-border tax laws
2025 Secondary Public Offering
Two Thousand Twenty Five Secondary Public Offering [Member]
Two thousand twenty five secondary public offering.
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Options forfeited and canceled (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Sale of Stock, Price Per Share
Offering per share price
Other Partner [Member]
Other.
Other Partner
Total intrinsic value of options exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Foreign
Current Foreign Tax Expense (Benefit)
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
RSUs and PSUs
RSUs and PSUs [Member]
RSUs and PSUs
Lease Contractual Term [Axis]
Lease Contractual Term [Axis]
Leases [Abstract]
Leases [Abstract]
Amendment Flag
Amendment Flag
Amendment Flag
Product and Service
Product and Service [Domain]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Income tax benefit at federal statutory rate
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Inventory Disclosure [Text Block]
Consolidated Financial Statement Details
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants issued to be purchase common shares
Net Loss Per Share
Earnings Per Share, Policy [Policy Text Block]
Treasury Stock [Policy Text Block]
Treasury stock policy.
Treasury Stock
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities and Equity [Abstract]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Disposal Group, Including Discontinued Operation, Other Assets, Current
Other current assets
Operating Lease, Measurement Input
Operating lease, measurement input
Operating Lease, Measurement Input
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
2020 Purchase and Sale Agreement
Purchase and Sale Agreement 2020 [Member]
Purchase and Sale Agreement 2020
Common Stock
Common Stock [Member]
Common Shares
Cybersecurity Risk Role of Management [Text Block]
Tax Credit Carryforward, Amount
Income tax research credits
Options granted (in dollars per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Change in control severance payment period for executives
Change In Control Severance Payment Period For Executives
Change in control severance payment period for executives.
Interest Receivable, Current
Accrued interest receivable
Lessee, Operating Lease, Liability, to be Paid, Year Three
2028
Amortization of Debt Discount (Premium)
Amortization of premiums (discounts), net
Amortization of premiums (discounts), net
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Shares issued under prefunded warrant exercise (in shares)
Stock Issued During Period, Shares, Prefunded Warrant Exercise
Stock issued during period, shares, prefunded warrant exercise.
Portion at Fair Value Measurement
Portion at Fair Value Measurement [Member]
Portion at Fair Value Measurement [Member] [Default]
Entity Address, Address Line One
Entity Address, Address Line One
Total deferred tax liabilities
Deferred Tax Liabilities, Gross
Deferred Tax Liabilities, Gross, Total
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Measurement Input, Market Participant Subtenant Borrowing Rate
Measurement Input, Market Participant Subtenant Borrowing Rate [Member]
Measurement Input, Market Participant Subtenant Borrowing Rate
Income Taxes
Income Tax, Policy [Policy Text Block]
Litigation matters, liabilities
Loss Contingency Accrual
Loss Contingency Accrual, Beginning Balance
Loss Contingency Accrual, Ending Balance
Merger and Acquisition Related Claims
Merger And Acquisition Related Claims [Member]
Merger and acquisition related claims.
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Name of Property [Axis]
Name of Property [Axis]
Biolojic Design Company [Member]
Biolojic design company.
Biolojic Design Member
Statement of Financial Position Location, Balance [Axis]
Balance Sheet Location [Axis]
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Deferred tax assets before valuation allowance
Deferred Tax Assets, Gross
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
April Two Thousand And Twenty Five At-The-Market Sales Agreement [Member]
April Two Thousand And Twenty Five At-The-Market Sales Agreement.
April 2025 ATM Sales Agreement
Purchases of investments
Payments to Acquire Debt Securities, Available-for-Sale
Inventory Disclosure [Abstract]
Inventory Disclosure [Abstract]
Net unrealized loss on available-for-sale investments
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Class of Warrant or Right [Axis]
Document Type
Document Type
Document Type
Income Taxes Paid, Net
Income Taxes Paid, Net, Total
Cash paid (refund) for income taxes, net
Type of Arrangement and Non-arrangement Transactions
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Amended And Restated Two Thousand Seventeen Performance Incentive Plan [Member]
Amended and restated two thousand seventeen performance incentive plan.
Amended and Restated 2017 Performance Incentive Plan
Payment made for milestone not achieved year one
Payment Made For Milestone Not Achieved Year One
Payment made for milestone not achieved year one.
Arrangements and Non-arrangement Transactions
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Entity Central Index Key
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Proceeds from Sales of Business, Affiliate and Productive Assets
Cash proceeds at closing
Net increase (decrease) in cash and cash equivalents
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Subsequent Event Type [Domain]
Schedule of Revenue by Geographic Area
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
Percentage of funding phase 3 development costs on an indication by indication basis borne
Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne
Percentage of funding Phase three development costs on an indication by indication basis borne.
Contract termination costs
Loss on Contract Termination
Contract termination costs
Contract termination and other restructuring costs
Weighted average antidilutive securities excluded from computation of earnings per share (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Potentially dilutive securities (in shares)
Disposal Group Classification [Domain]
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Unrecorded Unconditional Purchase Obligation, Purchases
Purchases made
Accounting Standards Update [Domain]
Proceeds from Issuance of Warrants
Proceeds from issuance of TCG pre-funded warrant
Astra Zeneca Ab
Astra Zeneca Ab [Member]
AstraZeneca AB.
Weighted-Average Remaining Contractual Life, Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Deconsolidation, Gain (Loss), Amount
Gain on asset sale
Gain on sale of the Huntsville manufacturing facility
Gain on asset sale
Gain on sale of the Huntsville manufacturing facility
Deferred tax assets:
Components of Deferred Tax Assets and Liabilities [Abstract]
Fair Value
Debt Securities, Available-for-Sale
Debt Securities, Available-for-Sale, Total
Fair Value
Indemnification Obligation
Indemnification Agreement [Member]
Tax positions related to current year:
Tax Positions Related To Current Year [Abstract]
Tax Positions Related To Current Year
Document Financial Statement Error Correction Flag
Document Financial Statement Error Correction [Flag]
Options exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Operating loss carryforwards, subject to expiration
Operating Loss Carryforwards, Subject To Expiration
Operating Loss Carryforwards, Subject To Expiration
Organization And Summary Of Significant Accounting Policies [Table]
Organization And Summary Of Significant Accounting Policies [Table]
Organization and summary of significant accounting policies.
Settlements
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Estimate of Fair Value Measurement
Estimate of Fair Value Measurement [Member]
Estimated Fair Value at
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Accrued expenses (including $994 and $3,403 as of December 31, 2025 and 2024, respectively, to a related party)
Total accrued expenses
Accrued Liabilities, Current
Net payable
Cost of goods sold
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Pursuant to the 2012 Purchase and Sale Agreement
Purchase And Sale Agreement [Member]
Purchase and sale agreement.
Current Fiscal Year End Date
Current Fiscal Year End Date
Liabilities Related to the Sales of Future Royalties
Liability Related To Sale Of Potential Future Royalties [Text Block]
Liability related to sale of potential future royalties.
TCG Crossover Fund II, L.P.
TCG Crossover Fund II, L.P.
TCG Crossover Fund I I, L P [Member]
Other operating costs
Other Cost and Expense, Operating
Provision for inventory obsolescence.
Provision For Inventory Obsolescence
Provision for net realizable value of inventory
Provision for inventory obsolescence
Entity Address, State or Province
Entity Address, State or Province
Beginning balance (in shares)
Ending balance (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Increase (Decrease) in Other Accrued Liabilities
Accrued expenses
Investment, Name [Domain]
Asset Acquisition [Domain]
Fair value of liabilities
Financial Liabilities Fair Value Disclosure
Financial Liabilities Fair Value Disclosure, Total
Preferred stock, shares outstanding (in shares)
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Third Street Facility
Third Street Lease [Member]
Third street lease.
Third St
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income (loss)
Gross unrealized gains
Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Research and Development Expense
Research and Development Expense, Policy [Policy Text Block]
Total common stock reserved for issuance
Common Stock, Capital Shares Reserved for Future Issuance
Total common stock reserved for issuance
Common stock reserved for issuance
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
Gain on Sale of the Huntsville Manufacturing Facility
Transaction costs and net working capital adjustment for sale of Huntsville manufacturing facility included in accounts payable and accrued expenses
Transaction Costs and Net Working Capital Adjustment for Sale of Huntsville Manufacturing Facility Included in Accounts Payable and Accrued Expense
Transaction costs and net working capital adjustment for sale of Huntsville manufacturing facility included in accounts payable and accrued expense.
Class of Warrant or Right [Domain]
Geographical
Geographical [Axis]
Commissions Due To Offering
Commissions due to offering.
Commissions
Contract Termination and Other Costs
Contract Termination and Other Costs [Member[
Contract Termination and Other Costs [Member[
Accounts Receivable [Member]
Interest and other non-trade receivables
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
State & local income taxes, net of federal income tax effect
Schedule of Stock-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Other
Comprehensive Loss
Comprehensive Income, Policy [Policy Text Block]
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options Shares Issued
Share based compensation arrangement by share-based payment award, equity instruments other than options shares issued.
Shares issued
Employee
Employee [Member]
Employee.
Schedule of Significant Components of Deferred Tax Assets and Liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
License and Collaboration Agreements
Collaborative Arrangement Disclosure [Text Block]
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Sublease Property, Plant And Equipment
Sublease Property, Plant And Equipment [Member]
Sublease Property, Plant And Equipment
Property, Plant and Equipment
Subsequent Event [Member]
Subsequent Event
Contract Termination Costs
Contract termination costs.
Contract termination costs
Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities
Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities
Operating leases, net
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Abstract]
Research and other credits
Deferred Tax Assets, Tax Credit Carryforwards, Research
Other assets
Other Assets, Noncurrent
Fair Value Measurement Inputs and Valuation Techniques [Table]
Short-term investments
Short-term investments
Debt Securities, Available-for-Sale, Current
Deferred Revenue Arrangement Type [Axis]
Antidilutive Securities
Antidilutive Securities [Axis]
Fair value of restricted stock vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Sales of investments
Proceeds from Sale of Debt Securities, Available-for-Sale
State
State and Local Jurisdiction [Member]
Transaction costs related to revised royalty payments
Transaction Costs Related To Revised Royalty Payments
Transaction Costs Related To Revised Royalty Payments
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income
Customer
Customer [Domain]
Derivative liability
Derivative Liability, Total
Derivative Liability
Reductions
Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions
Treasury stock, shares
Treasury Stock, Common, Shares
Ending balance (in shares)
Beginning balance (in shares)
Treasury shares outstanding
Non-cash interest expense
Non-cash interest expense on liabilities related to sales of future royalties
Non Cash Interest Expense Related To Sale Of Royalties
Non-cash interest expense related to sale of royalties.
Non-cash interest expense on liabilities related to the sales of future royalties
Non-cash interest expense on liabilities related to sales of future royalties
Non-cash interest expense on liabilities related to the sales of future royalties
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net working capital
Net working capital
Net working capital
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at December 31, 2025 or 2024, respectively
Preferred Stock, Value, Issued
Deferred:
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Summary of Gain Computation
Disposal Groups, Including Discontinued Operations [Table Text Block]
Assets Held for Sale
Income Taxes Disclosure [Line Items]
Income Taxes Disclosure [Line Items]
Income taxes disclosure.
Minimum
Minimum [Member]
Granted (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Bristol Myers Squibb Collaboration Agreement
Bristol Myers Squibb Collaboration Agreement [Member]
Bristol Myers Squibb collaboration agreement.
Financial Instrument [Axis]
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Two Thousand Twenty Five Public Offering [Member]
Two thousand twenty five public offering.
2025 Offering
Royalty monetization proceeds
Royalty Monetization Proceeds
Proceeds from sale of potential future royalties.
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment
Property, plant and equipment, net
Fair Value, Level 3
Level 3
Fair Value, Inputs, Level 3 [Member]
Payments to RPI
Partial Repayment Of Royalty Sale Proceeds
Partial repayment of royalty sale proceeds.
Aggregate payment of RPI
Income tax rate reconciliation impairment of goodwill.
Income Tax Rate Reconciliation Impairment Of Goodwill
Impairment of goodwill
Segment Reporting [Abstract]
Segment Reporting [Abstract]
Schedule of Portfolio of Cash and Investments in Marketable Securities
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Current liabilities:
Liabilities, Current [Abstract]
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options Reserved For Issuance
Share-based compensation arrangement by share-based payment award, equity instruments other than options reserved for issuance.
Shares reserved for issuance
Net assets sold
Net assets sold
Net assets sold
Net assets sold
Product sales
Product [Member]
Discovery Research And Other Programs [Member]
Discovery research and other programs.
Discovery Research and Other Programs
Less: unamortized transaction costs
Liabilities On Sale Of Future Royalties Unamortized Transaction Costs
Liabilities on sale of future royalties, unamortized transaction costs.
Third St. Facility
Third St. Facility [Member]
Third St. Facility
Schedule of Maturities of Operating Lease Receivables from Subleases
Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]
Sublease Income
Total sublease income
Services Agreements [Member]
Services agreements.
Services Agreements
Operating loss carryforwards
Operating Loss Carryforwards
Renewal term (in years)
Lessee, Operating Lease, Renewal Term
Proceeds from sale of future royalties
Proceeds From Sale of Future Royalties
Proceeds From Sale of Future Royalties.
Upfront and milestone payments received from license agreements
Upfront And Milestone Payments Received From License Agreements
Upfront and milestone payments received from license agreements.
Securities Purchase Agreement.
Securities Purchase Agreement [Member]
Securities Purchase Agreement
Accounts Receivable and Significant Customer Concentrations
Accounts Receivable And Significant Customer Concentrations [Policy Text Block]
Accounts receivable and significant customer concentrations.
Commitments and contingencies
Commitments and Contingencies
Lessee, Leases [Policy Text Block]
Leases
Percentage of preferred units outstanding
Percentage Of Preferred Units Outstanding
Percentage of preferred units outstanding.
Beginning balance (in dollars per share)
Ending balance (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Milestone [Axis]
Milestone [Axis]
Milestone [Axis]
Shares issued under equity compensation plans (in shares)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total
Accounts Receivable, Credit Loss Expense (Reversal)
Accounts receivable, credit loss expense (reversal)
General and administrative
General and Administrative Expense [Member]
General and Administrative Expense
Operating lease liabilities
Operating Lease, Liability
Percentage of Preferred Units Owned by Related Party Outstanding
Percentage of preferred units owned by related party outstanding.
Percentage of the preferred units owned by related party outstanding
Auditor Firm ID
Auditor Firm ID
Stockholders' Equity, Reverse Stock Split
Reverse stock split
Collaborative arrangement, success-based payments
Collaborative Arrangement, Success-Based Payments, Amount
Collaborative Arrangement, Success-Based Payments, Amount
Success payments (up to)
Scenario Forecast
Forecast [Member]
Reportable Geographical Components
Reportable Geographical Components [Member]
NKTR-255 (IL-15 receptor agonist)
NKTR Two Five Five [Member]
NKTR two five five.
Concentration Risk Benchmark
Concentration Risk Benchmark [Axis]
Sale of Equity Aggregate Maximum Public Offering Amount
Sale of equity aggregate maximum public offering amount.
Aggregate maximum public offering amount
Deferred Tax Assets, Liability Related to the Sale of Future Royalties
Deferred Tax Assets, Liability Related to the Sale of Future Royalties
Liabilities related to the sales of future royalties
Percentage of the common units outstanding
Percentage of the common units outstanding
Percentage of the common units outstanding
Common units owned
Common units owned
Common units owned
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Changes in valuation allowances
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Lease Contractual Term [Domain]
Lease Contractual Term [Domain]
Disposal Group, Including Discontinued Operation, Liabilities, Current
Disposal Group, Including Discontinued Operation, Liabilities, Current, Total
Current liabilities
Liabilities related to assets held for sale
Net Working Capital Adjustment Within Gain on Sale
Net working capital adjustment within gain on sale.
Net working capital adjustment
Stock-based compensation
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount
Baxalta Incorporated Or Takeda P L C
Baxalta Incorporated Or Takeda P L C [Member]
Baxalta Incorporated or takeda PLC.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Loss Contingencies [Table]
Loss Contingencies [Table]
Weighted average shares outstanding used in computing basic net loss per share (in shares)
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Scenario [Axis]
Preferred stock, shares designated (in shares)
Preferred Stock Share Designated
Preferred stock, shares designated.
Aggregate Intrinsic Value, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Stock-based compensation
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of Reconciliation of our U.S. Federal Statutory Tax Amount and Rate to Effective Amount and Rate
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Segments [Axis]
Investment in foreign subsidiary
Deferred Tax Liabilities, Investment in Noncontrolled Affiliates
Property, Plant and Equipment, Type
Long-Lived Tangible Asset [Domain]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Total cash and investments in marketable securities
Cash and investments in marketable securities
Cash Restricted Cash Cash Equivalents And Available For Sale Investments
Cash, restricted cash, cash equivalents, and available for sale investments.
Subsequent Events [Text Block]
Subsequent Events
Effective Income Tax Rate Reconciliation, Liabilities Related to the Sales of Future Royalties, Percent
Effective Income Tax Rate Reconciliation, Liabilities Related to the Sales of Future Royalties, Percent
Liabilities related to the sales of future royalties, net
Asset Acquisition, Consideration Transferred, Transaction Cost
Transaction costs
Transaction costs
Cash
Cash
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Capitalized research and development costs
Deferred Tax Asset, In-Process Research and Development
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Losses recorded in AOCI
Total stockholders’ equity
Beginning balance
Ending balance
Equity, Attributable to Parent
Subleases area Of leased space.
Subleases Area Of Leased Space
Subleases space (in sq ft)
Available For Sale Securities In Unrealized Loss Positions Number Of Positions Less Than One Year
Available for sale securities in unrealized loss positions number of positions less than one year.
Number of investments in unrealized loss positions
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Collaborative Arrangement, Committed Funding
Collaborative Arrangement, Committed Funding
Committed funding (up to)
Stock Options, RSUs and PSUs
Stock Options, RSUs And PSUs [Member]
Stock Options, RSUs And PSUs
Stock Options, RSUs And PSUs
Expiration of net operating loss carryforwards
Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards
Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss Carryforwards
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Non-cash Interest Expense On Liabilities Related To Sales Of Future Royalties Policy [Policy Text Block]
Non-cash interest expense on liabilities related to sales of future royalties policy.
Non-cash Interest Expense on Liabilities Related to the Sales of Future Royalties
Equity Method Investments
Equity method investment in Gannet BioChem
Type of Restructuring [Domain]
Type of Restructuring [Domain]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Equity Method Investment [Table]
Property, plant and equipment and Operating lease right-of-use assets
Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure
Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure
Property, plant and equipment and operating lease right-of-use assets
Treasury Stock
Treasury Stock, Common [Member]
Claim on net assets of Gannet BioChem - end of period
Equity Method Investment, Underlying Equity in Net Assets
Claim on net assets of Gannet BioChem - beginning of period
Claim on net assets of Gannet BioChem
Two thousand twenty two and two thousand twenty three restructuring plans.
Two Thousand Twenty Two and Two Thousand Twenty Three Restructuring Plans [Member]
2022 and 2023 Restructuring Plans
Mission Bay Facility
Mission Bay Lease [Member]
Mission bay lease.
Mission Bay Blvd. South
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan
United States
UNITED STATES
At-the-Market Offering
At the Market Offerings [Member]
At-the-market offerings.
Percentage of sharing in Phase 2 development costs
Percentage Of Sharing In Phase Two Development Costs
Percentage of sharing in Phase 2 development costs.
Common Stock Are Reserved For Future Issuance Table Text Block
Schedule of Shares of Common Stock Reserved for Future Issuance
Common stock are reserved for future issuance.
Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
2012 Purchase and Sale Agreement
Purchase and Sale Agreement 2012 [Member]
Purchase and Sale Agreement 2012
Other current assets (including $429 and $0 as of December 31, 2025 and 2024, respectively, from a related party)
Other current assets
Other Assets, Current
Measurement Input, Discount Rate
Measurement Input, Discount Rate [Member]
Income or loss from investment
Loss from equity method investment
Change in claim on net assets of Gannet BioChem
Loss from equity method investment
Schedule of Unrecognized Tax Benefits
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Resale of common stock issuable upon exercise of warrant
Resale of Common Stock Issuable Upon Exercise of Warrant
Resale of common stock issuable upon exercise of warrant.
Mission Bay Facility
Mission Bay Facility [Member]
Mission Bay Facility
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Segment Reporting, Other Segment Item, Amount
Other segment expenses
Total other segment expenses
Plan Name
Plan Name [Domain]
Other assets
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets, Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Entity
Entity [Domain]
Number of renewal options
Lessee, operating lease, number of renewal options.
Lessee, Operating Lease, Number Of Renewal Options
Buildings
Building [Member]
Agreement term
Agreement term
Agreement term
Matching 401(k) employer contribution, maximum amount
Deferred Compensation Arrangement with Individual, Contributions by Employer
Cost of goods sold
Cost of Product and Service Sold
Cost of Goods and Services Sold, Total
NKTR Zero One Six Five [Member]
NKTR zero one six five.
NKTR-0165 (tumor necrosis factor receptor type II agonist)
Impairment of right-of-use assets and property, plant and equipment
Impairment of other property, plant and equipment
Impairment of right-of-use asset and property, plant and equipment
Total impairment of right-of-use assets and property, plant and equipment
Total impairment of right-of-use assets
State
Current State and Local Tax Expense (Benefit)
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Certificates of deposit
Certificates of Deposit [Member]
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]
Lessor, Operating Lease, Payment to be Received, Year Two
2027
Treasury stock, at cost; 0 shares and 552,307 shares as of December 31, 2025 and 2024, respectively
Treasury Stock, Value
Treasury Stock, Value, Total
Treasury stock, at cost; 0 shares and 552,307 shares as of December 31, 2025 and 2024, respectively
Restructuring Plan [Axis]
Restructuring Plan [Axis]
Related and Nonrelated Parties [Axis]
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Other adjustments
Long-Lived Assets
Property, Plant and Equipment, Policy [Policy Text Block]
Entity Address, City or Town
Entity Address, City or Town
Potential Development And Regulatory Milestones
Potential development and regulatory milestones.
Potential future additional development and regulatory milestones (up to)
Stock Repurchased During Period, Shares
Sale of stock shares repurchased
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Number of operating business segment
Number of Reportable Segments
Security Exchange Name
Security Exchange Name
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Other adjustments
Current:
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Obligations under Director and Officer Indemnifications per incident
Obligations Under Director And Officer Indemnifications Per Incident
Obligations under director and officer indemnifications per incident.
Counterparty Name
Counterparty Name [Axis]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Loss before benefit for income taxes and equity method investment
Concentration Risk Type
Concentration Risk Type [Domain]
Nektar-358
Nektar-358 [Member]
Nektar-358
Measurement Input Type [Domain]
Measurement Input Type [Domain]
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Foreign tax effects
Nektar 214
Nektar 214 [Member]
Nektar 214.
Total inventory
Inventory
Inventory, Net
Non Cash Royalties [Member]
Non Cash Royalties.
NonCash Royalties
Purchase Agreement
Share Purchase Agreement [Member]
Share purchase agreement.
Underwriting discounts
Underwriting Discounts Due To Offering
Underwriting discounts due to offering.
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Measurement Basis [Axis]
Measurement Basis [Axis]
Range
Statistical Measurement [Domain]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants
Total current assets
Assets, Current
Total stock-based compensation
Stock-based compensation
Share-Based Payment Arrangement, Expense
Document Period End Date
Document Period End Date
Equity Method Investments and Joint Ventures [Abstract]
Average volatility factor
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
Title of Individual [Axis]
Title and Position [Axis]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Fair Value, Level 3
Restructuring Plan
Restructuring Plan [Member]
Restructuring plan.
Compensation expense in connection with 401(k) retirement plan
Defined Contribution Plan, Cost
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Number of Shares, Exercisable (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Payment made for milestone not achieved year two
Payment Made For Milestone Not Achieved Year Two
Payment made for milestone not achieved year two.
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Restricted Stock Units (RSU)
Restricted Stock Units (RSUs) [Member]
Loss Contingency Nature
Loss Contingency Nature [Axis]
Loss Contingency, Nature
Loss Contingency, Nature [Domain]
Restructuring, Impairment, and Other Activities Disclosure [Text Block]
Restructuring and Impairment
Restructuring and Impairment Policy [Policy Text Block]
Restructuring and impairment policy.
Restructuring
Expiration of net operating loss carryforwards
Effective Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards
Effective tax rate reconciliation expiration of net operating loss carryforwards.
Deferred Tax Liabilities, Net
Deferred Tax Liabilities, Net, Total
Net deferred tax assets (liabilities)
Current Income Tax Expense (Benefit)
Total current income tax benefit
Loss on revaluation of liability related to the sale of future royalties
Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties
Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties
Non-cash loss on revaluation of liability related to the sale of future royalties
Loss on revaluation of liability related to the sale of future royalties
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Effects of changes in tax laws or rates enacted in the current period
Total liabilities
Liabilities
Net payable
Financial Instruments [Domain]
Financial Instruments [Domain]
Percentage of regulatory milestones payments will be reduced under certain conditions
Percentage Of Development Milestones Payments To Be Received Under Certain Conditions
Percentage of development milestones payments, to be received under certain conditions.
UCB
U C B Pharma [Member]
UCB Pharma.
Service period for stock-based compensation award granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period
Liability Related To Sale Of Potential Future Royalties [Abstract]
Liability Related To Sale Of Potential Future Royalties [Abstract]
Liability related to sale of potential future royalties.
Equity Method Investments [Policy Text Block]
Equity Method Investment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
License And Collaboration Agreements [Abstract]
License and collaboration agreements.
Foreign tax effects
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
Milestone One
Milestone One [Member]
Milestone One [Member]
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
Disposal Groups, Including Discontinued Operations [Table]
Asset Purchase Agreement [Member]
Asset purchase agreement.
Asset Purchase Agreement
Weighted average shares outstanding used in computing diluted net loss per share (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Entity File Number
Entity File Number
Number Of Milestones
Number Of Milestones
Number of Milestone
Sublease Operating Lease Right of Use Assets
Sublease Operating Lease Right of Use Assets [Member]
Sublease Operating Lease Right of Use Assets
Operating Lease Right-of-Use Assets
Cover [Abstract]
Cover
Measurement Input Type [Axis]
Measurement Input Type [Axis]
Forfeited and canceled (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Royalties liability, measurement input
Royalties Liability, Measurement Input
Royalties Liability, Measurement Input
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss before benefit for income taxes and equity method investment
Loss before benefit for income taxes and equity method investment
Revenue
Revenue Benchmark [Member]
Scenario [Domain]
Weighted average maturity period
Investments, Weighted Average Maturity Period
Investments, Weighted Average Maturity Period
Number of shares authorized
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Sale of Stock
Sale of Stock [Domain]
License, collaboration and other revenue
License Collaboration And Other Revenue [Member]
License collaboration and other revenue.
Warrant Exercised Prior Notice Period
Warrant exercised prior notice period.
Warrant exercised prior notice period
Segment Reporting
Segment Reporting Disclosure [Text Block]
General and administrative
General and Administrative Expense
General and Administrative Expense, Total
Inventory and Significant Supplier Concentrations
Inventory And Significant Supplier Concentrations [Policy Text Block]
Inventory and significant supplier concentrations.
Subsequent Event [Table]
Revenue by geographic area
Geographic Areas, Revenues from External Customers [Abstract]
Purchase Commitment, Remaining Minimum Amount Committed
Purchase commitments related to contract manufacturing, clinical development and certain other items
Organization And Summary Of Significant Accounting Policies [Line Items]
Organization And Summary Of Significant Accounting Policies [Line Items]
Organization and summary of significant accounting policies.
Other
Deferred Tax Assets, Other
Effects of changes in tax laws or rates enacted in the current period
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
Operating Lease, Expense
Lease expense
Document Financial Statement Restatement Recovery Analysis [Flag]
Restructuring Charges
Restructuring Charges, Total
Restructuring, impairment, and costs of terminated program
Expense recognized during the period
Weighted- Average Remaining Contractual Life (in Years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Property and equipment estimated useful lives
Property, Plant and Equipment, Useful Life
Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Schedule of Future Minimum Lease Payments for Operating Leases
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Other
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Employee Severance
Employee Severance [Member]
Income Loss Before Equity Method Investment
Income (loss) before equity method investment.
Loss before equity method investment
Loss before equity method investment
Domestic
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Reported Value Measurement
Reported Value Measurement [Member]
Eli Lilly And Company
Eli Lilly And Company [Member]
Eli Lilly and Company.
Prepaid research and development expenses
Prepaid Research And Development Expenses [Member]
Prepaid Research And Development Expenses
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
Organization and Summary of Significant Accounting Policies
Non-cash royalty revenue related to sales of future royalties
Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount
Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount
Common stock, shares outstanding (in shares)
Beginning balance (in shares)
Ending balance (in shares)
Common Stock, Shares, Outstanding
Common shares outstanding
Less: current portion
Operating lease liabilities, current portion
Operating Lease, Liability, Current
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Depreciation and amortization expenses
Depreciation, Depletion and Amortization
Depreciation, Depletion and Amortization, Total
Accrued Research And Development Expenses Current
Accrued research and development expenses current.
Accrued research and development expenses
Cybersecurity Risk Management Processes Integrated [Flag]
Document Transition Report
Document Transition Report
Research and Development Expense, Total
Research and development expenses
Research and development
Research and development (including $2,636 and $277 for the year ended December 31, 2025 and 2024, respectively, from a related party)
Total impairment of sublease assets
Impairment of right-of-use assets and property, plant and equipment
Asset Impairment Charges
Operating Leases
Lessee, Operating Leases [Text Block]
Repurchase of common stock from Bristol-Myers Squibb
Payments for Repurchase of Common Stock
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Schedule of Benefit for Income Taxes
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Weighted- Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Federal
Current Federal Tax Expense (Benefit)
Shares issued under offering, net of underwriting discounts and offering costs
Stock Issued During Period, Value, New Issues
Schedule of Stock Option Activity Under Equity Incentive Plans
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Stockholders' Equity
Equity [Text Block]
Shares issued (in shares)
Shares, Issued
Discontinued Operations and Disposal Groups [Abstract]
Measurement Input, Expected Dividend Rate [Member]
Dividend yield
Schedule of Restricted Stock Unit Award Activity
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Other
Deferred Tax Liabilities, Other
Cybersecurity Risk Management Processes Integrated [Text Block]
Net loss
Net loss
Aggregate Intrinsic Value, Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Inventory
Increase (Decrease) in Inventories
Increase (Decrease) in Inventories, Total
Gannet BioChem
Gannet Bio Chem [Member]
Gannet bio chem.
Operating Lease, Cost
Operating lease expense
Dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Operating lease, payments
Operating Lease, Payments
ASSETS
Assets [Abstract]
SFJ Pharmaceuticals [Member]
SFJ Pharmaceuticals
SFJ
Average risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Jefferies LLC
Jefferies LLC [Member]
Jefferies LLC.
Name of Property [Domain]
Name of Property [Domain]
Preferred units owned by a related party
Preferred Units Owned by a Related Party
Preferred units owned by a related party.
Sales Agreement
Sales Agreement [Member]
Sales agreement.
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Equity Securities, FV-NI, Measurement Input
Cash flows from investing activities:
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Accounts payable (including $137 and $0 as of December 31, 2025 and 2024, respectively, to a related party)
Accounts Payable, Current
Accounts Payable, Current, Total
Lapses in statute of limitations
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Schedule of Income Before Income Tax, Domestic and Foreign
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Lessor, Operating Lease, Payment to be Received, Year One
2026
Research and Development Expense [Member]
Research and Development Expense
Research and development
Other Operating Segment [Member]
Other Segment
Schedule of Liability Related to Potential Future Royalties
Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]
Schedule Of Liability Related To Sale Of Potential Future Royalties
Repayment due of GST refunds
Goods And Service Tax Refunds Repayment Due
Goods and service tax refunds repayment due.
Proceeds from sale of assets
Proceeds from Sale of Productive Assets
Proceeds from Sale of Productive Assets, Total
Federal
Deferred Federal Income Tax Expense (Benefit)
Shares issued under equity compensation plans
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total
Fair value of equity method investment in Gannet BioChem - Level 3 of Fair Value Hierarchy
Fair Value of Equity Received as Part of Proceeds From Sale
Fair value of the equity we received as part of the proceeds from sale.
Restructuring Cost and Reserve [Line Items]
Restructuring Cost and Reserve [Line Items]
Gross cash and non-cash proceeds
Gross cash and non-cash proceeds
Gross cash and non-cash proceeds
Gross cash and non-cash proceeds
Loss on revaluation of liability related to the sale of future royalties
Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross
Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross
Fair Value Measurements
Fair Value Measurement, Policy [Policy Text Block]
Payment For Development Milestones
Payment for development milestones.
Tax Credit Carryforward, Expiration Date
Tax credit carryforward, expiration beginning date
Common unit, price per unit
Common unit, price per unit
Common unit, price per unit
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized Tax Benefits [Roll Forward]
Book value in excess of fair value
Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Book Value in Excess of Fair Value
Property, plant and equipment, and operating lease right of use asset, book value in excess of fair value.
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Non-cash royalty revenue related to the sales of future royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]
Non-cash royalty revenue related to sale of future royalties.
Non-cash royalty revenue related to the sales of future royalties
Accrued contract termination costs
Accrued Contract Termination Costs, Current
Accrued Contract Termination Costs, Current
2030 and thereafter
Lessor Operating Lease Payments To Be Received After Four Years and Thereafter
Amount of lease payment to be received by lessor for operating lease after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payment Arrangement [Abstract]
Total unrecognized compensation costs
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Sale of Stock
Sale of Stock [Axis]
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised
Proceeds from shares issued under equity compensation plans and TCG pre-funded warrant
Percentage revenue from customers
Concentration Risk, Percentage
Liability Related To Sale Of Future Royalties [Roll Forward]
Liability Related To Sale Of Future Royalties [Roll Forward]
Liability Related To Sale Of Future Royalties
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Equity Method Investment
Nektar 0165 [Member]
Nektar 0165.
Nektar 0165
Nektar 0165
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Options forfeited and canceled (in dollars per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited and canceled (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Money market funds
Money Market Funds [Member]
Related and Nonrelated Parties [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Effective Income Tax Rate Reconciliation, Non Deductible Expense For Liability Related Sale Of Future Royalties, Amount
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
Non-cash interest expense on liabilities related to sales of future royalties
At the Market Offering [Member]
At the Market Offering [Member]
At-the-Market Offering
Lessor, Operating Lease, Payment to be Received
Gross Lease Receivable
Other long-term liabilities
Other Liabilities, Noncurrent
Consolidated Entities
Consolidated Entities [Axis]
Restructuring Plan [Domain]
Restructuring Plan [Domain]
Legal Entity
Legal Entity [Axis]
Liabilities related to the sales of future royalties, net
Liabilities related to the sales of future royalties, net
Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
Liability related to sale of potential future royalties non current net of issuance costs.
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Letter of credit
Letters of Credit Outstanding, Amount
Outstanding, beginning balance (in dollars per share)
Outstanding, ending balance (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Beginning balance
Ending balance
Unrecognized Tax Benefits
Lessor, Operating Lease, Payment to be Received, Year Four
2029
Capital in Excess of Par Value
Additional Paid-in Capital [Member]
Liability Related to the Sale of Future Royalties [Line Items]
Liability Related To Sale Of Future Royalties [Line Items]
Liability related to sale of future royalties.
Income Statement Location
Statement of Income Location, Balance [Axis]
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Contract asset
Disposal Group, Including Discontinued Operation, Contract With Customer Asset, Current
Disposal Group, Including Discontinued Operation, Contract With Customer Asset, Current.
Equity Method Investments, Fair Value Disclosure
Fair value of equity method investment in Gannet BioChem - Level 3 of Fair Value Hierarchy
Lessee Operating Lease Liability Payments Due After Year Four
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
2030 and thereafter
Director
Director [Member]
Sale of stock consideration received
Sale Of Stock Consideration Received
Sale of stock consideration received.
Subsequent Event Type [Axis]
Percentage of regulatory milestones payments will be reduced if conditions occur
Percentage Of Development Milestones Payments To Be Received If Conditions Occur
Percentage of development milestones payments, to be received, if conditions occur.
Accrued compensation
Employee-related Liabilities, Current
Employee-related Liabilities, Current, Total
Cash flows from financing activities:
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Weighted-average expected life
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Schedule of Equity Method Investments [Line Items]
Total lease payments
Lessee, Operating Lease, Liability, to be Paid
Less: portion representing interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Research credits
Research credits
Fair Value of Equity Method Investment in Gannet Bio Chem Received in Exchange for Sale of Huntsville Manufacturing Facility
Fair value of equity method investment in gannet bio chem received in exchange for sale of huntsville manufacturing facility.
Fair value of equity method investment in Gannet BioChem received in exchange for sale of Huntsville manufacturing facility
Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties
Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds
Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions
Equity Components
Equity Components [Axis]
Proceeds From Payments For Sale Of Huntsville Manufacturing Facility Net
Proceeds from payments for sale of huntsville manufacturing facility net.
Proceeds (payments) relating to the sale of the Huntsville manufacturing facility, net
Total non-operating income (expense), net
Nonoperating Income (Expense)
Equity Component
Equity Component [Domain]
Asset Class [Axis]
Asset Class [Axis]
Net proceeds
Net proceeds
Net proceeds
Sale Of Manufacturing Facility [Policy Text Block]
Sale of manufacturing facility.
Sale of Manufacturing Facility
Long term investment maturity period
Long Term Investment Maturity Period
Long term investment maturity period.
Document Annual Report
Document Annual Report
Customer
Customer [Axis]
Stock options term under equity incentive plans
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction
Depreciation, Depletion and Amortization, Nonproduction, Total
Depreciation and amortization expense
Collaborative Arrangements
Collaborative Arrangement, Accounting Policy [Policy Text Block]
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total
Changes in unrecognized tax benefits
Statement of Comprehensive Income [Abstract]
Statement of Comprehensive Income [Abstract]
Maximum
Maximum
Maximum [Member]
Range
Statistical Measurement [Axis]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Options exercised (in dollars per share)
Segment, Reconciliation of Other Items from Segments to Consolidated [Table]
Common stock, $0.0001 par value; 390,000,000 shares and 300,000,000 shares authorized at December 31, 2025 and 2024, respectively; 20,378,832 shares and 12,937,308 shares issued at December 31, 2025 and 2024, respectively; 20,378,832 shares and 12,385,001 shares outstanding at December 31, 2025 and December 31, 2024, respectively
Common Stock, Value, Issued
Consolidation, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
Royalty revenue
Royalty [Member]
Roche [Member]
Roche.
Roche
Net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Deferred Tax Assets, Operating Loss Carryforwards, Total
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Net expense reimbursements from collaboration partner
Net Expense Reimbursements From Collaboration Partner
Net expense reimbursements from collaboration partner.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Long-Lived Asset Impairment
Accrued Liabilities, Total
Accrued expenses
Net payable
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State & local income taxes, net of federal income tax effect
Unrecognized tax benefits, period may increase or decrease due to tax examination
Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change
Unrecognized tax benefits, period increase (decrease) reasonable period of change
Secondary Offering [Member]
Secondary offering.
Secondary Offering
Entity Public Float
Entity Public Float
Preferred stock, shares authorized (in shares)
Preferred Stock, Shares Authorized
Total operating costs and expenses
Costs and Expenses
Proceeds from sale of royalty rights
Proceeds From Sale Of Potential Future Royalties Gross
Proceeds from sale of potential future royalties gross.
Disposal Group Including Discontinued Operation Contract Asset Net
Disposal Group Including Discontinued Operation Contract Asset Net
Contract asset, net
Payment of transaction related to purchase and sale agreement
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved
Opdivo
Opdivo [Member]
Opdivo.
Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents
Cash, Cash Equivalent, and Investment [Table Text Block]
Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent
Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total
Effects of cross-border tax laws
Employee Stock [Member]
Employee Stock Purchase Plan
Entity Registrant Name
Entity Registrant Name
Gross Unrealized Losses
Gross unrealized losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Entity Voluntary Filers
Entity Voluntary Filers
Customer Concentration Risk
Customer Concentration Risk [Member]
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Treasury Stock, Shares, Acquired
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Treasury stock reissued
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense), Total
Other income
Other income (expense), net
Other income (expense), net (including $1,110 and $0 for the year ended December 31, 2025 and 2024, respectively, from a related party)
State
Deferred State and Local Income Tax Expense (Benefit)
Subsequent Events [Abstract]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Schedule Of Equity Method Investments
Schedule Of Equity Method Investments [Table Text Block]
Schedule of equity method investments.
Consolidated Entities
Consolidated Entities [Domain]
Income Tax Expense (Benefit)
Provision (benefit) for income taxes
Benefit for income taxes
Benefit for income taxes
Pfizer
Pfizer [Member]
Pfizer
Restructuring Reserve [Roll Forward]
Restructuring Reserve [Roll Forward]
Gross proceeds
Net proceeds from issuance of common stock
Proceeds from offering, net
Operating costs and expenses:
Costs and Expenses [Abstract]
Target maturity period
Investmnets, Target Maturity Period
Investmnets, Target Maturity Period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Assumptions Used to Calculate the Fair Value of the Equity Method Investment
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Entity Common Stock, Shares Outstanding (in shares)
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Disposal Group Classification [Axis]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive income (loss)
Consolidation Items
Consolidation Items [Axis]
Percentage of Number of Shares for Warrant Exercised
Percentage of number of shares of warrant exercised.
Percentage of number of shares of warrant exercised
Payments during the period
Payments for Restructuring
Payments during the period
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Gain (Loss) on Investments
Gain (Loss) on Investments, Total
Loss from our investment
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted (in shares)
Total assets
Assets
Weighted-Average Remaining Contractual Life, Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Income Statement [Abstract]
Income Statement [Abstract]
Schedule of Restructuring and Related Costs [Table]
Restructuring Cost [Table]
Related Parties
Related Parties [Policy Text Block]
Related parties.
Reductions
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Stock-Based Compensation
Share-Based Payment Arrangement [Policy Text Block]
Cash, Cash Equivalent, and Marketable Security [Text Block]
Cash and Investments in Marketable Securities
Total deferred income tax expense
Deferred income tax expense
Deferred Income Tax Expense (Benefit)
Stock Issued During Period, Shares, New Issues
Sale and issuance of shares
Shares issued under offering, net of underwriting discounts and offering costs (in shares)
Novo Nordisk
Novo Nordisk [Member]
Novo Nordisk.
Vested and released (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Diluted net loss per share (in dollars per share)
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Diluted net loss per share (in dollars per share)
Income Taxes Disclosure [Table]
Income Taxes Disclosure [Table]
Income taxes disclosure.
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Summary of Significant Expense Categories and Consolidated Net Loss
Payment of transaction related to purchase and sale agreement if threshold is not achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved
Relationship to Entity [Domain]
Title and Position [Domain]
Asset Acquisition [Axis]
Non-cash royalty revenue
Non-cash royalty revenue related to the sales of future royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non cash royalty revenue related to sale future royalties.
City Area Code
City Area Code
Other comprehensive loss
Other Comprehensive Income (Loss), Net of Tax
Potential future additional payments for development milestones
Potential Development Milestones
Potential development milestones.
Potential Development Milestones
Schedule Of Leases [Table]
Schedule Of Leases [Table]
Schedule Of Leases [Table]
Auditor Name
Auditor Name
Supply Agreements
Supply Agreements [Member]
Supply agreements.
Counterparty Name
Counterparty Name [Domain]
Research credits
Income tax research credits
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Operating lease liabilities
Deferred Tax Assets, Lease Liability
Deferred Tax Assets, Lease Liability
Variable lease expense
Variable Lease, Cost
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Weighted average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio
Reverse stock split, ratio
Total lease expense
Lease, Cost
2017 Performance Incentive Plan
Two Thousand Seventeen Performance Incentive Plan [Member]
Two Thousand Seventeen Performance Incentive Plan
Future Royalties
Future Royalties
Future Royalties [Member]
Cash, Cash Equivalents, and Investments in Marketable Securities
Cash and Cash Equivalents, Policy [Policy Text Block]
Equity method investment dividends or distributions
Proceeds from Equity Method Investment, Distribution
Property, plant and equipment, net
Property, plant and equipment, net
Property, Plant and Equipment, Net
Property, plant and equipment, net
Property and equipment, net
Foreign
Deferred Foreign Income Tax Expense (Benefit)
Subleases aggregate lease payments
Subleases Income, To Be Received
Subleases Income, To Be Received
Loss from operations
Operating Income (Loss)
Issuance of prefunded warrant
Issuance of prefunded warrant
Issuance of prefunded warrant
Accumulated Deficit
Retained Earnings [Member]
Offering period
Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period
Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period
Amount exchanged to remove cap on royalties
Amount exchanged to remove cap on royalties
Amount exchanged to remove cap on royalties
Asset Acquisition, Consideration Transferred
Asset Acquisition, Consideration Transferred, Total
Consideration in cash, net of transaction costs
Measurement Input, Price Volatility [Member]
Volatility factor
Payments of Stock Issuance Costs
Payments of offering costs associated with issuance of common stock
Underwriting discounts, commissions and offering costs
Commissions costs
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Investments unrealized loss positions for less than 12 months
Unrecorded Unconditional Purchase Obligation
Unrecorded Unconditional Purchase Obligation, Including Lease Not yet Commenced, Total
Unrecorded Unconditional Purchase Obligation, Total
Minimum purchase commitments
November Two Thousand And Twenty Five At-The-MarketSales Agreement [Member]
November Two Thousand and Twenty Five At-The-MarketSales Agreement [Member].
November 2025 ATM Sales Agreement
Weighted average discount rate, percent
Operating Lease, Weighted Average Discount Rate, Percent
Operating lease liabilities, less current portion
Operating lease liabilities, less current portion
Operating Lease, Liability, Noncurrent
Level 1
Fair Value, Inputs, Level 1 [Member]
Class of Stock [Line Items]
Class of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Underwritten Public Offering [Member]
Underwritten public offering.
Underwritten Public Offering
2025 Offering
Lessor, Operating Lease, Payment to be Received, Year Three
2028
Schedule of Lease Expense
Lease, Cost [Table Text Block]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Auditor Location
Auditor Location
Liabilities related to the sales of future royalties—beginning balance
Liabilities related to the sales of future royalties – ending balance
Liability Related To Sale Of Potential Future Royalties Non Current
Liability Related To Sale Of Potential Future Royalties Non Current
Investments in marketable securities
Investments, Fair Value Disclosure
Investments, Fair Value Disclosure, Total
Investments in marketable securities
Schedule of Other Current Assets [Table Text Block]
Schedule of Other Current Assets
Non-operating income (expense):
Nonoperating Income (Expense) [Abstract]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Rest of World
Non-US [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Shar
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Liability for litigation
Estimated Litigation Liability
Corporate notes and bonds
Corporate Debt Securities [Member]
Income Tax Authority
Income Tax Jurisdiction [Domain]
Entity Interactive Data Current
Entity Interactive Data Current
Income Statement Location
Statement of Income Location, Balance [Domain]
Fair Value Measurement [Domain]
Fair Value Measurement [Domain]
Percentage of sharing production costs
Percentage Of Sharing In Production Costs
Percentage of sharing in production costs.
Cash flows from operating activities:
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Share Based Payment Arrangement Option And RSUs [Member]
Share Based Payment Arrangement Option And RSUs.
Stock Options and RSUs Outstanding
Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]
Schedule of Other Segment Expense Items Included within Net Loss
Organization
Organization Policy [Text Block]
Organization.
Deferred tax liabilities:
Components of Deferred Tax Liabilities [Abstract]
Entity Tax Identification Number
Entity Tax Identification Number
Revenue:
Revenues [Abstract]
Securities Related Claims
Securities Related Claims [Member]
Securities related claims.
Non-Securities Related Claims
Non Securities Related Claims [Member]
Non-securities related claims.
Maturities of investments
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Clinical Development Contract Manufacturing And Other Third Party Costs
Clinical development contract manufacturing and other third party costs.
Clinical development, contract manufacturing and other third party costs
Effect of foreign exchange rates on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Employee Related Costs
Employee related costs.
Employee costs
Local Phone Number
Local Phone Number
Sale of stock repurchased cash consideration
Sale of stock repurchased cash consideration.
Sale Of Stock Repurchased Cash Consideration
Auditor Opinion [Text Block]
Leases [Line Items]
Leases [Line Items]
Leases [Line Items]
Unrecognized tax benefits, interest recognized
Unrecognized Tax Benefits, Interest on Income Taxes Expense
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Revenue
Lessee, Operating Lease, Liability, to be Paid, Year Four
2029
Manufacturing equipment
Manufacturing Laboratory And Other Equipment [Member]
Manufacturing laboratory and other equipment.
Corporate commercial paper
Commercial Paper [Member]
Number of common stock shares available for stock options grants (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares available for future issuance
Recognized over a weighted-average period
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Maximum 401(k) per employee, percentage of annual salary
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent
Affiliated Entity [Member]
Affiliates
Schedule of Stock by Class [Table]
Stock, Class of Stock [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company